Skip to main content

Table 3 Results of base case and worst-case scenario analysis over a time horizon of two, four, six, eight and ten years

From: Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States

Scenario

Treatment

Cost ($)*

QALY

Incremental Cost ($)

Incremental Effectiveness

(QALY gained)

ICER ($/QALY)

10-year time horizon

 Base-case

Usual care

116,156

6.84

1,662,765

0.45

3,655,352

Lumacaftor/ivacaftor

1,778,921

7.29

 Worst-case

Usual care

116,156

6.84

1,677,901

0.20

8,480,265

Lumacaftor/ivacaftor

1,794,056

7.04

2-year time horizon

 Base-case

Usual care

30,469

2.23

531,606

0.07

7,311,801

Lumacaftor/ivacaftor

562,075

2.3

 Worst-case

Usual care

30,469

2.23

532,262

0.06

9,292,285

Lumacaftor/ivacaftor

562,731

2.28

4-year time horizon

 Base-case

Usual care

51,850

3.56

852,463

0.15

5,835,535

Lumacaftor/ivacaftor

904,313

3.70

 Worst-case

Usual care

51,850

3.56

855,802

0.09

9,554,343

Lumacaftor/ivacaftor

907,652

3.65

6-year time horizon

 Base-case

Usual care

72,361

4.77

1,148,863

0.24

4,869,328

Lumacaftor/ivacaftor

1,221,224

5.00

 Worst-case

Usual care

72,361

4.77

1,155,718

0.12

9,263,760

Lumacaftor/ivacaftor

1,228,079

4.89

8-year time horizon

 Base-case

Usual care

94,274

5.86

1,418,488

0.34

4,173,169

Lumacaftor/ivacaftor

1,512,761

6.20

 Worst-case

Usual care

94,274

5.86

1,429,656

0.16

8,861,944

Lumacaftor/ivacaftor

1,523,930

6.02

  1. QALY Quality adjusted life year, ICER Incremental-cost effectiveness ratio
  2. *All costs are expressed in USD-2016